Connetics Licenses Technology for the Treatment of Hyperhidrosis.

PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced it has obtained an exclusive, worldwide license to certain patented technology that has potential utility in the treatment of hyperhidrosis. Connetics has initiated a formulation development program utilizing this technology with the goal of developing a safe, effective, well-tolerated and cosmetically elegant topical formulation. The Company intends to begin clinical development immediately after completion of the formulation development activities. Financial terms include upfront, milestone and royalty payments.

"For patients with hyperhidrosis, excessive sweating often results in daily embarrassments in professional, academic and social life. Patients often suffer both physically and psychologically," said Lincoln Krochmal, M.D., Executive Vice President of Research and Development for Connetics. "Treatment options range from topical therapy, local injections, or surgery. The currently available topical therapy options tend to irritate the skin, while the injections need to be repeated and are frequently painful. We have an exciting opportunity to develop a novel treatment for this disorder by incorporating this licensed technology into one of Connetics' innovative topical delivery vehicles."

About Hyperhidrosis

Hyperhidrosis is a disorder characterized by excessive sweating that is estimated to affect more than 7 million Americans. This excessive sweating can occur in the hands (palmar hyperhidrosis), in the armpits (axillary hyperhidrosis), or in the feet (plantar hyperhidrosis), and may be triggered by stress, emotion, or exercise, but can also occur spontaneously. Patients with palmar hyperhidrosis often find it awkward to shake hands with others and difficult to grasp objects. Those who suffer from axillary hyperhidrosis often have stained clothes as a result of excessive sweat from their underarms. Patients with plantar hyperhidrosis are left with moist socks and shoes, as well as increased foot odor.

About Connetics

Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(R) (clindamycin) Foam, 1%. Connetics is developing Desilux(TM) (desonide) VersaFoam-EF, 0.05%, a low-potency topical steroid formulated to treat atopic dermatitis; Primolux(TM) (clobetasol propionate) VersaFoam-EF, 0.05%, a super high-potency topical steroid formulation to treat atopic dermatitis and plaque psoriasis; Extina(R) (ketoconazole) VersaFoam-HF, 2%, to treat seborrheic dermatitis and Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne. Connetics' product formulations are designed to improve the management of dermatological diseases and provide significant product differentiation. In Connetics' marketed products, these formulations have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com.

Forward Looking Statements

Except for historical information, this press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Connetics expects, believes or anticipates will or may occur in the future, including, particularly, statements about its formulation and clinical development programs, are forward-looking statements. All forward-looking statements are based on certain assumptions made by Connetics' management based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond Connetics' control, and which could cause actual results or events to differ materially from those expressed in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks and other factors that are discussed in documents filed by Connetics with the Securities and Exchange Commission from time to time, including Connetics' Annual Report on Form 10-K for the year ended December 31, 2004 and Form 10-Q filed for the quarter ended September 30, 2005. Forward-looking statements represent the judgment of the Company's management as of the date of this release, and Connetics disclaims any intent or obligation to update any forward-looking statements.

Press Release Code: (CNCT-G)